PIA
HUMA icon

Powell Investment Advisors’s Humacyte HUMA Stock Holding History

Powell Investment Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,000
Closed -$59.6K – 149
2023
Q4 		$59.6K Buy
21,000
+9,000
+75% +$23.1K 0.03% 135
2023
Q3 		$35.2K Buy
+12,000
New +$39.7K 0.02% 132
2022
Q3 		– Sell
-14,000
Closed -$45K – 131
2022
Q2 		$45K Buy
+14,000
New +$77.8K 0.03% 129

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Powell Investment Advisors's HUMA Position: Q1 2024 in Review

Powell Investment Advisors sold out of Humacyte (HUMA) in Q1 2024, closing a stake of 21,000 shares — an estimated $59.6K sold.

Powell Investment Advisors first reported a position in HUMA in Q2 2022 and held it in 3 quarters. The position peaked at $59.6K in Q4 2023. 96 funds tracked by Wall St. Rank hold HUMA as of Q1 2024.

  • Powell Investment Advisors reported no remaining Humacyte position as of Q1 2024 after selling out during the quarter.
  • Powell Investment Advisors sold 21,000 Humacyte shares in Q1 2024, an estimated $59.6K.
  • Powell Investment Advisors first reported a position in Humacyte in Q2 2022 and held it in 3 quarters.
  • Powell Investment Advisors's Humacyte position peaked at $59.6K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Humacyte as of Q1 2024.

Based on Powell Investment Advisors's 13F filing for Q1 2024, filed 16 Apr 2024.